



北京友谊医院
BEIJING FRIENDSHIP HOSPITAL

Department of Pathology

Yan-Lin Zhang, MD.
Doctor, Department of Pathology, Beijing Friendship Hospital
Capital Medical University

2020/3/13

Dear editor:

We would like to thank the reviewers for their valuable suggestions. Our manuscript has been revised based on every comment from the reviewers (see the next pages for details). We have also asked MedSci colleagues of native English speakers to proof read the manuscript and they have already gave us the certification of English editing. We sincerely hope that the paper is now suitable for publication on World Journal of Clinical Cases. If you have any questions, do not hesitate to contact us.

Regards,

张燕林

Yan-Lin Zhang, MD.
Doctor, Department of Pathology, Beijing Friendship Hospital
Capital Medical University
Tel: +86-13581824188 E-mail: zyl84131421@163.com

Reviewer 1:

Question:

The citation numbers in the text and in the reference list are not consistent; Moreover, there is some incorrect spelling and sentences. Some spaces are missing in the tables, in the figure legends and in the reference list.

Answer:

We have adjusted the consistency in the text and in the reference list. e.g., Discussion, third paragraph: "Wehkamp et al. [7]", changed into "Wehkamp et al. [6]".

We have revised the sentence "...found that all of their analyzed cases, except two, had blastic features, which was are considered extensively aggressive" in the third paragraph of Discussion part, into "we also found that all of their analyzed cases, except two, had blastoid morphology, this type was considered extensively aggressive".

We have revised all the incorrect spelling and added spaces missed in the text, in the tables, in the figure legends and in the reference list.

All the revisions have been highlighted by color.

Reviewer 2:

Question:

Please describe the chemotherapy regimen for Case 3 and Case 5 in the listed review (Table 1), and I don't think that there is anything else to add, change or delete.

Answer:

The chemotherapy regimen for Case 3 and Case 5 have been added in the listed review (Table 1):

Case 3: Chemotherapy Regimen is R-CHOP;

Case 5: Chemotherapy Regimen is Etoposide 100 mg per day and prednisone 25 mg per day for 5 days per month for 11 months, then maintained on 5 mg prednisone daily.